Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer
This study has been completed.
Study NCT00031187   Information provided by Seattle Genetics, Inc.

First Received on February 27, 2002.   Last Updated on October 21, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Prostatic Neoplasms
Additional conditions recognized in this trial
Neoplasms
More general conditions related to this trial
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms
Interventions listed in this trial
Taxotere (docetaxel)
Additional drug interventions recognized in this trial
Antibodies, Monoclonal
Antineoplastic Agents
Docetaxel
Doxorubicin
Immunoconjugates
More general drug interventions related to this trial
Antibiotics, Antineoplastic
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Seattle Genetics, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services